

Poster listing *as at 23 November 2022*

Poster number	Paper Title
Pharmacy Practice (APSA) - Wednesday 30 November	
400	A Retrospective, Longitudinal Study of Antibiotic Prescribing at a Western Australian Hospital Zahraa Abbas, Curtin University
401	Enhancing guideline implementability through communication design strategies: A systematic scoping review Steven Agiasotis, The University of Sydney
402	Co-designing the PRIME tool Dr Nagham Ailabouni, The University of Queensland
403	Patient characteristics and experiences with pharmacy immunisation services in New Zealand Dr Mudassir Anwar, University of Otago, New Zealand
404	Impact of partnered pharmacist medication charting on potentially inappropriate medications use Tesfay Mehari Atey, University of Tasmania
405	Telepharmacy: the way of the future? Anna Barwick, The University of Queensland
406	Health and medication related goals of care of older people with polypharmacy Aagam Bordia, The University of Sydney
407	Exploring consumer's perspective of pharmacist delivering COVID-19 vaccinations Tien Bui, University of South Australia
408	COVID-19 and Mental illness: pandemic perceptions and adherence to public health measures. Tien Bui, University of South Australia
409	Development of a survey to evaluate deprescribing guideline dissemination and implementation Chun Hei Justin Cheng, The University of Sydney
410	COVID-19's impact on pharmacy innovation and legislative changes Maria Cooper, University of South Australia
411	Is amoxicillin a suitable antibiotic for home intravenous administration? Dr Petra Czarniak, Curtin University
413	Clinical pharmacists' participation in ward rounds in Australian hospitals: The current practice Assoc Prof Lisa Kalisch Ellett, University of South Australia
414	What is impacting clinical pharmacists' participation in ward rounds? Assoc Prof Lisa Kalisch Ellett, University of South Australia
415	Clinic-based pharmacists: the missing link Vivienne Lim, Sir Charles Gairdner Hospital
416	Pharmacist consultations in hospitalised older surgical patients Jacinta Lin, The University of Sydney
417	Sleep Health Management in Residential Aged Care Facilities Elissar Mansour, The University of Sydney
418	Do entry-level pharmacy students have different personal characteristics? Prof Carlo Marra, University of Otago, New Zealand
419	Predictors of pharmacist's and pharmacy students' involvement in patient-centred pharmacy services Prof Carlo Marra, University of Otago, New Zealand
420	Pharmacy students' role expectations in practice: A comparison between NZ and Canada Prof Carlo Marra, University of Otago, New Zealand
421	Optimising adherence to allopurinol and gout management: people with gout's perspectives Toni Michael, The University of Sydney
422	20 years of obstetric medicines information calls—a timeline of patterns and trends Nabeelah Mukadam, King Edward Memorial Hospital
423	Investigating medicinal cannabis as a treatment for spasticity and muscle spasms Xenia Nastatos, The University of Sydney
424	Are Essential Medicines Accessible? Lachlan Oldfield, The University of Sydney
425	A scoping review of health-system guidelines for opioid dispensing William Olsen, The University of Queensland
426	The codesign and evaluation of an osteoporosis module by teachers and pharmacists Jonathan Phuong, Sydney University
427	The importance of medication information to community dwelling individuals Dr Joy Spark, University of New England

Pharmacy Practice (APSA) *continued*

428	Pharmacists' acceptability of perinatal depression screening in community pharmacies: A content analysis Clara Strowel, The University of Sydney
429	Prevalence of fluoropyrimidine-induced toxicities in patients receiving fluoropyrimidine-based chemotherapy Dr Vijay Suppiah, University of South Australia
430	Barriers and enablers to the use of parenteral methotrexate: a scoping review Jiun Ming Tan, University of South Australia
431	Evaluation of available medication management resources for carers of people with dementia Gabrielle Widjaja, The University of Sydney
432	Application of user-centred co-design principles to address barriers in therapeutic drug monitoring Sherilyn Wong, University of South Australia
433	Exploring health literacy responsiveness within remote pharmacy organisations Helen Wood, The University of Western Australia
434	Exploring Australian pharmacists' perspectives and attitudes towards the down-scheduling of melatonin Kingston Yeung, The University of Sydney
435	Determination of physical compatibility of oxycodone and co-administered drugs via intra-venous ports Souha Youssef, University of South Australia
436	Psychotropic adverse drug event monitoring tools for residential care: a systematic review Brigid McInerney, Monash University
437	Prevalence and predictors of long-term opioid use following orthopaedic surgery in Australia Dr Jonathan Penm, The University of Sydney
438	Understanding pharmacists' scope of practice in managing asthma in the community Weiqi Wu, The University of Sydney

Toxicology (ASCEPT) – Thursday 1 November

439	The impact of medicinal cannabis legalisation and re-scheduling on poisonings in Australia Sara Allaf, The University of Sydney
440	Paracetamol (acetaminophen) hepatotoxicity increases in the presence of an added herbal compound Susan Britza, The University of Adelaide
441	Could herbal soup be a potentially unrecognised cause of hepatotoxicity at autopsy? Susan Britza, The University of Adelaide
442	The impact of pharmacist only up-scheduling of modified release paracetamol on poisonings Dr Rose Cairns, The University of Sydney
443	Biochemical changes in liver and intestinal cells induced by weight loss supplements Emily Davies, Murdoch University
444	QSAR models to detect endocrine-disrupting chemicals acting at the retinoic acid receptor Raymond Lui, The University of Sydney
445	Bisphenols depress contractile activity of gut smooth muscle in rats Prof Maloy Bikash Mandal, Banaras Hindu University, India
446	Nitromethane toxicokinetics estimated from a case study Dr Frank Reimann, Hunter New England Local Health District
447	Plastic released toxic chemical delays the gastric emptying time: Experimental evidence Dr Atanu Roy, Banaras Hindu University, India
448	Poisonings in older people with dementia: a systematic scoping review Ilsa Wojt, The University of Sydney
449	Biochanin A and quercetin modulate simvastatin toxicity in HepG2 cultures Joshua Zechner, The University of Adelaide
450	Machine learning exploration of per and poly fluoroalkyl substance (PFAS) toxicity Dr Slade Matthews, The University of Sydney

Drug Discovery (ASCEPT) - Wednesday 30 November

451	Tumour Microenvironmental Features Direct Stem Cells Fate Arian Ansardamavandi, The University of Melbourne
452	Fragment screening against stabilised $\alpha 1A$- and $\alpha 1B$-adrenoceptors identifies novel sub-type selective antagonist Dr Alaa Abdul-Ridha, The Florey Institute of Neuroscience and Mental Health
453	Assessment of glucose-lowering constituents in Teucrium Polium extract Yaser Albadr, Curtin University
454	Validation of positive allosteric modulators for DOR to treat gastrointestinal motility disorders Sadia Alvi, Monash University
455	Gs priming of non-Gs protein activation and signalling at the glucagon-likepeptide-1 receptor John Azieta, Monash University

Drug Discovery (ASCEPT) *continued*

456	Solving the P2X1 receptor structure – a target for male contraception Felix Bennetts, Monash University
457	Molecular dynamics simulations reveals a novel cholesterol binding site for P2X7 receptors Zheng Chen, The University of Sydney
458	The orexin receptors exhibit spatiotemporal signalling mechanisms in response to endogenous ligands Natasha Dale, Harry Perkins Institute of Medical Research
459	Computational modelling of heterotrimeric P2X7 receptors Sophie De Salis, The University of Sydney
460	Measuring intracellular calcium signalling dynamics between cell-in-cell structures using genetically-encoded calcium indicators Ellen Janke, The University of Queensland
461	Triple negative breast cancer: Screening for the invasion amplifying cAMP-calcium feedforward loop Terrance Lam, Monash University
462	Drug repurposing screen targeting PARP in high grade serous ovarian cancer Bayley Matthews, University of Newcastle
463	Investigating the pharmacological relationship between GPR161 and spexin-1 Kinjal Patel, UNSW Sydney
464	Assessment of store operated calcium entry in cellular ageing models Vijayraghavan Seshadri, University of Tasmania
465	Screening assays for inhibitors against SARS-CoV-2 Spike protein and cell entry Dr Pdraig Strappe, Curtin University
466	Antiviral activity of Selective Serotonin reuptake inhibitors against enteroviruses Dr Pdraig Strappe, Curtin University
467	The search for a ligand for the pro-atherosclerotic orphan GPCR, GPR146 Brendan Wilkins, UNSW Sydney
468	Quantification of the inhibitory effect of neurofibromin 1 (NF1) using biosensors Michelle Xiaomeng Xu, Monash University
469	Aptamer-based Phenylalanine Sensor for Cell Culture Monitoring Yiling Yang, The University of Melbourne
470	Investigating the atypical DRY motif of the potential lipid-lowering orphan receptor GPR146 Jack Zhang, UNSW Sydney
471	The role of RunX2 in calcium-related signaling pathways in breast cancer cells Junkai Zhang, The University of Queensland
472	The influence of soluble microenvironment on tumour cell cytotoxicity of chemotherapeutics Xiaodan Zhang, The University of Melbourne

Neuropharmacology (ASCEPT) - Wednesday 30 November

473	Polypharmacy with high Drug Burden Index (DBI) reduces function with sex differences Gizem Gemikonakli, The University of Sydney
474	Hypocretin-1 receptor antagonism and inhibitory control during the go/no-go task Assoc Prof Laura Jacobson, Florey Institute of Neuroscience and Mental Health
475	Desensitising Properties of Gain-of-function GABRB3 variants influence the severity of DEE Susan Lin, The University of Sydney
476	Investigating an orexin receptor 2 structure-function relationship with C-terminus mutants Henry Purbrick, Harry Perkins Institute for Medical Research
477	Role of endocannabinoids in fear learning in a murine neuropathic pain model Saima Sadia, The University of Sydney

Cardiovascular (ASCEPT) - Thursday 1 November

479	Exploring cardiac GPCRs for effective fibrosis treatment Joel Coffie, Monash University
480	Intermittent fasting protects against chronic cerebral hypoperfusion-induced cerebrovascular transcriptomic changes Dr Michael De Silva, La Trobe University
481	Use of oral effective dose 50 (ED50) to optimise antihypertensive drug dose Prof Simon Dimmitt, University of Western Australia
482	Unravelling the intracellular signalling pathways in CGRP-induced vasorelaxation in rat coronary arteries Lucy Donovan, University of Oxford, UK
483	Australian patients' perspectives on oral anticoagulant initiation in atrial fibrillation Eyob Alemayehu Gebreyohannes, University of Western Australia

Cardiovascular (ASCEPT) *continued*

484	Effects of acute and chronic trimethylamine-N-oxide and simulated diabetes in cardiac myoblasts Saba Naghipour, Griffith University
485	Influence of natriuretic peptides on vasculature– Cell culture for drug testing? Christine Rager, Monash University
486	Sex differences in risk of diabetes-associated cardiovascular events with SGLT2i versus GLP-1RAs Abhipree Sharma, Monash University
487	Antiarrhythmic effects of phenytoin, a novel heart failure diastolic ryanodine channel inhibitor Melanie Spratt, Queensland University of Technology
488	Gene expression analyses of Tas1R taste receptors in cardiometabolic disease Mariah Stavrou, UNSW Sydney
489	Metabolic profiling of mice with deletion of orphan GPCR, GPR37L1 Margaret Mouat, UNSW
490	High-definition flow cytometry of the mouse kidney for single cell studies Jake Robertson, La Trobe University
491	Impairment of prostacyclin signalling: impact of ageing and coronary spasm Kate Spuler, The University of Adelaide

Respiratory and Inflammation (ASCEPT) - Thursday 1 November

492	Challenging the inhibitory/excitatory paradigm: Increased GABAergic inhibition can lead to epilepsy Prof Mary Chebib, The University of Sydney
493	Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University
494	CXCL17 is a novel MRGPRX2 agonist: Importance of cellular context Jie Ding, The University of Melbourne
495	Adding a dimension to biomechanical cues underlying IPF Avanka Gunatilaka, The University of Melbourne
496	Cell shape: A determinant of TGF-β functionality? Chiao Hwei Lee, The University of Melbourne
497	Characterising the contribution of Casein Kinase 1δ in the fibrogenesis of IPF Stephanie Zhang, The University of Melbourne

Education (APSA and ASCEPT) - Thursday 1 November

498	Academic student partnership in developing an online workshop to address vaccine hesitancy Dr Suzanne Caliph, Monash University
499	A faculty approach to unify the Honours program in Pharmaceutical Science Dr Betty Exintaris, Monash University
500	Student perceptions of pharmacology laboratory experiences: Computer simulation vs in-person "wet" lab Dr Yeong Hann Ling, Monash University
501	Using clinical case studies to build work relevant skills Dr Suong Ngo, The University of Adelaide
502	Student perspectives on the effects of cognitive enhancers and attitudes towards use Dr Anna-marie Babey, University of New England
503	How do technology-enhanced learning strategies affect biomedical and healthcare students' engagement? Michelle Chen, The University of Sydney
504	Going digital – students' perceptions of electronic laboratory notebooks (ELNs) Dr Betty Exintaris, Monash University

Pharmacy and Pharmaceutical Sciences Education (APSA) - Thursday 1 November

506	Examining the First Nations cultural safety content in Australian Pharmacy Schools Alexander Burke, The University of Sydney
507	Clinical impact of Antibigrams to optimise antimicrobial prescribing and patient health outcomes Assoc Prof Chris Freeman, The University of Queensland
508	Exploring current teamwork skill aptitudes of first year Pharmaceutical Science undergraduate students Dr Nilushi Karunaratne, Monash University
509	Pharmacy students' health literacy knowledge: A qualitative exploratory study Helen Wood, The University of Western Australia

Pharmacogenomics (ASCEPT) - Thursday 1 November

510	Non-DPYD gene variants associated with severe fluoropyrimidine toxicity Dr Katie Burns, University of Auckland, New Zealand
511	Pharmacogenomic implications of polypharmacy in hospitalised patients taking antipsychotic medications Dr Vijay Suppiah, University of South Australia
512	Dihydropyrimidine dehydrogenase (DPD) phenotyping methodologies: A literature review Dr Vijay Suppiah, University of South Australia
513	Investigating how polypharmacy and deprescription alter the hepatic proteome in aged mice Kevin Winardi, The University of Sydney
514	Outcomes and popPKs of antiviral drugs used in COVID-19 patients: A review Dr Suong Ngo, The University of Adelaide

Pharmacoepidemiology (ASCEPT) - Wednesday 30 November

515	The use of psychotropic medication in autistic young people in Western Australia Roselyne Bulonza, Curtin University
516	Prescribing patterns in very elderly patients in Christchurch, New Zealand Assoc Prof Matt Doogue, Te Whatu Ora Waitaha & University of Otago
517	Deprescribing heart failure medications in older people: a systematic review and meta-analysis Mai Duong, The University of Sydney
518	Prescribing of antiviral agents for COVID-19 in a large tertiary hospital Dr Joshua Inglis, Flinders Medical Centre
519	Trends in the utilisation of antiepileptic drugs following ischemic stroke Stella Jung-Hyun Kim, Monash University
520	Prevalence and association of antipsychotic drugs with falls in hospitalised older adults Prof David Le Couteur, Sydney University
521	Trends in incidences and mortality of hip fractures and associated risk factors Miriam Tim Yin Leung, Monash University
522	Medicine use in people with cystic fibrosis before and after modulator therapy Louise Lord, Monash University
523	Can we accurately predict future dementia in middle-aged adults? Dr Gopisankar Mohanannair Geethadevi, Monash University
524	Opioid deprescribing interventions for patients at transitions of care: A scoping review Jeffery Wang, The University of Sydney
525	Audit of data sharing by pharmaceutical companies for anticancer medicines Natansh Modi, Flinders University

Drug Disposition and Response (ASCEPT) - Wednesday 30 November

526	Between patient variability in drug disposition of large vs small molecules Assoc Prof Hesham Al-Sallami, University of Otago, New Zealand
527	Suppressing resistance of hypermutable Pseudomonas aeruginosa in a dynamic in-vitro biofilm model Siobhonne Breen, Monash University
528	Investigating the phenotypic plasticity of glioblastoma stem cells Willem du Preez, The University of Sydney
529	Using recombinant DNA technology to produce a delivery system for genetic drugs Yuzhang Li, The University of Queensland
530	Metabolic footprinting in a hollow-fibre infection model: Ceftolozane-tazobactam versus Pseudomonas aeruginosa Jessica Tait, Monash University
531	PK/PD indices cannot predict ciprofloxacin versus Pseudomonas aeruginosa with resistance mechanisms outcomes Alice Terrill, Monash University

Urogenital and Gastrointestinal (ASCEPT) - Wednesday 30 November

533	The effects of sildenafil on porcine distal ureteral contractions Asst Prof Iris Lim, Bond University
534	Severe hyperglycaemia impairs bladder contractility in a murine model of diabetes mellitus Dr Donna Sellers, Bond University
535	Gut dysbiosis in refractory hyperammonaemic syndrome post lung-transplant: Bystander or bad guy? Dr Tess Evans, College of Intensive Care Medicine
536	Aurocyanide is an active metabolite of auranofin for its anti-liver fibrosis effect Prof Keon Wook Kang, Seoul National University, South Korea
537	Global gut sampling: Implementing the ICU Prospective Observational Embedded Microbiome Study (POEMS) Catarina Wylde, University of Western Australia

Clinical Pharmacology (ASCEPT) - Thursday 1 November

505	The patient perspective: understanding the breast cancer medication management process Elizabeth Heard, University of New South Wales
538	Serious statin-associated myotoxicity in Indigenous Australians - a literature case series 2010-2020 Dr Genevieve Gabb, South Australia Health
539	Development of a PBPK model for Irbesartan in different CYP2C9 genotypes Pureum Kang, Sungkyunkwan University, South Korea
540	PBPK modeling and simulation for glipizide related to CYP2C9 genetic polymorphism Pureum Kang, Sungkyunkwan University, South Korea
541	Preventing urate-lowering therapy induced gout flares: a systematic review and network meta-analysis Dorsa Maher, University of South Australia
542	Development of Plasma Assay for Tyrosine Kinase Inhibitors Angus Mcpherson, University of Newcastle
543	Vanquish the vancomycin trough: the AUC strikes back Marie-Claire Morahan, Te Whatu Ora Waitaha, New Zealand
544	Validated UHPLC-MS/MS assay for quantification of opioids used for cancer pain management Dr Stefan Musolino, The University of Adelaide
545	Inhibition of cancer stem cells of MDA-MB-231 and MCF-7 by phenethyl isothiocyanate Dr Suong Ngo, The University of Adelaide
546	Using electronic prescription and laboratory data to assess prescribing practice Lorna Pairman, University of Otago, New Zealand
547	PBPK modeling of glimepiride in different CYP2C9 genotypes Hyejung Park, Sungkyunkwan University, South Korea
548	PBPK modeling of gliclazide in different CYP2C9 and CYP2C19 genotypes Hyejung Park, Sungkyunkwan University, South Korea
549	Immunosuppressant drug concentrations are assay-specific Dr Frank Reimann, Hunter New England Local Health District
550	Development of medication management guidance resources for people with dementia and carers. Dr Mouna Sawan, The University of Sydney
552	Prospective Study of A Clinical Quality Intervention (SMAART) to identify and challenge children with "low risk" penicillin and cephalosporin Dr Duaa Gaafar, The University of Melbourne
553	Phase 1a/1b trial of a tight junction regulator (IMU-856) for coeliac disease Dr Tom Polasek, Certara
554	Which patients are accessing medicinal cannabis under the Special Access Scheme Dr David Taylor, Eastern Health
555	Vancomycin AUC optimisation using minimal plasma concentration monitoring Assoc Prof Matt Doogue, Te Whatu Ora Waitaha & University of Otago, New Zealand

Pharmaceutical Science (APSA) - Thursday 1 November

556	3D printed estradiol buccal film: Design effect on release kinetics Sadikmahdi Hussen Abdella, University of South Australia
557	Development of a novel pH-buffered alginate gel for resistant wound infections Fatima Abid, University of South Australia
558	Fabrication of novel hydrogels from oxidized inulin crosslinked gelatin for drug delivery Dr Franklin Afinjuomo, University of South Australia
559	Triton X-100 alternative surfactants for split-virus influenza vaccine Abdulsalam Alharbi, The University of Sydney
560	Pharmacokinetics of Bee Venom Phospholipase A2 in rats using a sandwich ELISA Soon Uk Chae, The Catholic University of Korea, South Korea
562	Development of PBPK models to predict the effect of rabepazole on vismodegib Seong Jun Jo, The Catholic University of Korea, South Korea
563	Measurement of P_{app} using HiPSC-IECs and prediction pharmacokinetic profiles using PBPK models Chae Bin Lee, The Catholic University of Korea, South Korea
564	New Adjuvants to Bring Back Life to Old Antibacterials - Fosfomycin and Meropenem Elissar Mansour, The University of Sydney
565	Economic and time-efficient method for API extraction from equine pharmaceutical formulations Thabata Muta, University of South Australia
566	Development of remdesivir and ebselen containing inhalable dry powder for COVID-19 Tushar Saha, University of Otago, New Zealand
567	Development of LC-MS/MS Analysis for Pergolide in Equine Plasma Dr Yunmei Song, University of South Australia

Pharmaceutical Science (APSA) *continued*

568	5-fluorouracil and leucovorin predictive pharmacokinetics after administration of standard treatment and Deflexifol™ Dr Tahlia Meola, University of South Australia
569	Palmitoylethanolamide (palmidrol) as an analgesic and anti-inflammatory treatment for diabetic-related peripheral neuropathy Emily Pickering, The University of Queensland
570	Pharmacokinetic-pharmacodynamic modeling and simulation in the dosing of methotrexate Jiun Ming Tan, University of South Australia

Innovation and Industry (ASCEPT) - Thursday 1 November

571	Transcriptome analysis of rapidly maturing CLEFF4 and age matched parent Caco2 cells Dr Andrew Crowe, Curtin University
-----	---